Market
BMS halts Phase 1 development of acute myeloid leukemia treatment Orum Therapeutics has no obligation to return $100 million upfront payment

Orum Therapeutics’ asset transfer agreement with U.S. pharmaceutical company Bristol Myers Squibb (BMS) for a candidate treatment for acute myeloid leukemia has ended. The company is not obligated to return the upfront payment it has already received.
Orum Therapeutics disclosed on the 17th that BMS had decided to discontinue clinical development of BMS-986497 (ORM-6151) and notified the company that no further milestone payments would be due. The company listed the 16th, when it received notice from BMS in the U.S., as both the date the event occurred and the date of the decision.
On Oct. 30, 2023, Orum Therapeutics entered into an asset transfer agreement with BMS for ORM-6151, an acute myeloid leukemia treatment using the TPD²-GSPT1 platform, and received an upfront payment of $100 million.
BMS had been conducting a Phase 1 trial of BMS-986497 (ORM-6151) in the U.S., Europe and Canada. After reviewing clinical data from the program, BMS decided to discontinue development of ORM-6151.
Orum Therapeutics said it is not obligated to return the upfront payment it has already received. The agreement was signed before the company was listed on the KOSDAQ market.
The company said it plans to focus its capabilities on research and development of its own pipeline using its DAC platform. It made the disclosure because the milestone payments it had expected to receive exceeded 10% of its assets, based on its 2025 business report.

BIOBOOK TEAM
biobookmedia@biobook.co.kr
Medtronic to Acquire Contego Medical for $380 Million, Strengthening Carotid Treatment Portfolio

AstraZeneca wins Soliris antitrust lawsuit, with court finding no patent abuse

Alphabet Subsidiary Isomorphic Raises $5 Billion for AI Drug Development

Google Subsidiary Isomorphic Raises Another $5 Billion in Funding in Six Months

Lilly invests $7.9 billion in cancer-targeting technology company in fourth deal in 6 weeks

Samsung Biologics Completes 2.665 Trillion Won Rights Offering; New Shares to List Nov. 30